Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners
15 juil. 2019 16h10 HE
|
Interpace Diagnostics Group, Inc.
Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET PARSIPPANY NJ, July 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the...
Interpace Diagnostics Announces Coverage of Molecular Thyroid Testing by Independence Blue Cross
20 juin 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY NJ, June 20, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that its ThyGeNEXT™ and ThyraMIR® tests for thyroid cancer are now covered by...
Interpace Diagnostics Announces Presentation at the World Congress on Thyroid Cancer
13 juin 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Rome, ITALY, June 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that...
Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
13 mai 2019 16h05 HE
|
Interpace Diagnostics Group, Inc.
Quarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase Conference Call and Webcast Monday May 13, 2019 at 4:30...
Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week
09 mai 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Company to Host Fellowship and Key Opinion Leader Programs PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that data from an...
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019
06 mai 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, May 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc., (IDXG:NASDAQ) announced today that it will report its first quarter 2019 financial results after the close of...
Interpace Diagnostics Announces Publication of Important New Data on Thyroid Test Performance
01 mai 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Data from Registry Study Confirms the Value of ThyGenX® and ThyraMIR® in a Clinical Setting PARSIPPANY, NJ, May 01, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc....
Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation
25 avr. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Pennsylvania and Connecticut Labs Both Receive Accreditation PARSIPPANY, NJ, April 25, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has...
Interpace Diagnostics Announces New York State Approval
23 avr. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
State of New York Approves Commercialization of ThyraMIR® Now in Three Specimens PARSIPPANY, NJ, April 23, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today...
Interpace Diagnostics Announces New Coverage of Thyroid Testing by Medica
02 avr. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Key Regional Health Plan Further Expands Number of Covered Lives to Over 280 Million PARSIPPANY, NJ, April 02, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced...